CClinicalTrials.gg
Sign In
CompletedNCT01155102Updated Jan 23, 2018

Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions

An interventional study of Anastrozole in Breast Cancer, sponsored by Roxane Laboratories. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-23.

Sponsored by Roxane Laboratories · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The objective of this study was to prove the bioequivalence of Anastrozole Tablet under fasted conditions.

02

Conditions studied

  • Breast Cancer
03

In context

Lead sponsor

Roxane Laboratories is the lead sponsor of 98 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion criteria

Exclusion Criteria:

  • Positive test for HIV, Hepatitis B, or Hepatitis C.
  • Treatment with known enzyme altering drugs.
  • History of allergic or adverse response to anastrozole or any comparable or similar product.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Interventions

  • DrugAnastrozole

    1 mg tablet

    Also known as: ARIMIDEX

06

What researchers measure

Primary outcomes

  1. bioequivalence determined by statistical comparison Cmax

    Time frame: 31 days

07

Study locations

1 site
  • Bio-Kinetic Clinical Applications
    Springfield, Missouri 65802, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01155102
Lead sponsor
Roxane Laboratories
First posted
Jul 1, 2010
Start date
Apr 2006
Primary completion
May 2006
Completion
May 2006
Last update
Jan 23, 2018

Study contacts

Dennis Morrison, D.O.
principal investigator · Bio-Kinetic Clinical Applications

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Roxane Laboratories

Start the discussion